

金铁锁地上部分化学成分研究

文 波^{1,2}, 李 博², 沈云亨^{1,2*}¹福建中医药大学 药学院, 福州 350108;²中国人民解放军第二军医大学 药学院 天然药物化学教研室, 上海 200433

摘要: 运用柱色谱方法, 对金铁锁地上部分的 80% 乙醇提取物进行系统的化学成分研究, 从中共分离得到 11 个化合物。利用理化性质及 ESI-MS, NMR 光谱分析法, 分别鉴定为麦芽酚(1), 尼克酰胺(2), 尿嘧啶核苷(3), 2'-脱氧尿苷(4), 胸嘧啶核苷(5), 2'-脱氧胸苷(6), 尿嘧啶(7), 1-O-(4-羟甲基苯基) α -L-吡喃鼠李糖苷(8), 苄基- β -D-吡喃葡萄糖苷(9), (6R,9R)-3-氧代- α -紫罗兰醇-9-O- β -D-吡喃葡萄糖苷(10) 和川牛膝甾酮(11)。所有化合物均为首次从该植物中分离得到。

关键词: 金铁锁; 地上部分; 化学成分

中图分类号: R284. 2

文献标识码: A

Chemical Constituents from the Aerial Parts of *Psammosilene tunicoides*WEN Bo^{1,2}, LI Bo², SHEN Yun-heng^{1,2*}¹School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fujian 350108, China;²Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Abstract: Eleven compounds were isolated from the aerial parts of *Psammosilene tunicoides* by means of column chromatography. Their structures were identified as maltol (1), nicotinamide (2), uridine (3), deoxyuridine (4), thymidine (5), deoxythymidine (6), uracil (7), 1-O-(4-hydroxymethylphenyl) α -L-Rhamnopyranoside (8), benzyl- β -D-glucopyranoside (9), (6R,9R)-3-oxo- α -ionol-9-O- β -D-glucopyranoside (10) and capitasterone (11), respectively. All compounds were isolated from *P. tunicoides* for the first time.

Key words: *Psammosilene tunicoides*; aerial parts; chemical constituents

Introduction

Psammosilene tunicoides W. C. Wu et C. Y. Wu is the only species in the genus *Psammosilene* growing in Sichuan, Yunnan, Tibet and Guizhou provinces of China. As a Yunnan folk medicine, it has been long used for stopping bleeding, relieving pain and promoting blood circulation^[1]. The crude saponins obtained from this plant exhibited relieving pain, anti-inflammation and regulating the immune function^[2]. In searching for bioactive constituents from this plant, several kinds of compounds have been reported from the roots of this plant, including triterpenoid saponins, cyclic peptides, and carboline alkaloids^[3]. To our best knowledge, how-

ever, the chemical investigation of the aerial parts of *P. tunicoides* had not yet been investigated. In this study, the isolation and structural elucidation of 11 known compounds from the ethanol extract of the aerial parts of *P. tunicoides* are presented. All compounds were isolated from *P. tunicoides* for the first time.

Experimental

General experimental procedures

NMR spectral data were recorded on Bruker Avance 500 and 600 MHz NMR spectrometers. Chemical shifts were recorded as δ values. The ESI-MS data were acquired on an Agilent-1100-LC /MSD-Trap-XCT mass spectrometer (Agilent, USA). TLC was done on pre-coated silica gel 254 plates (Huanghai, 0.15-0.20 mm thick for TLC analysis, 0.40-0.50 mm thick for preparative TLC). Column chromatography was performed using silica gel (200-300 mesh and 100-200 mesh)

Received: June, 9 2013 Accepted: September 5 2013

Foundation Item: Project supported by National Major Project of China (2012ZX09502001-005)

* Corresponding author Tel: 86-21-81871245; E-mail: shenyunheng9217018@yaho. com. cn

(Huiyou Silica Gel Development Co. Ltd, Yantai, P. R. China), RP-C₁₈ (GHODS AQ 12S50, Japan) and Sephadex LH-20 (GE Healthcare Bio-Science AB, Sweden).

Plant materials

The aerial parts of *P. tunicoides* were collected in Lijiang, Yunnan province, China, in July 2006 and identified by Prof. Li-Shan Xie, Kunming Institute of Botany, the Chinese Academy of Sciences, China. The voucher specimen (No. 2006071015) was deposited with the Herbarium of the School of Pharmacy, Second Military Medical University.

Extraction and isolation

The aerial parts of *P. tunicoides* (13 kg) was macerated and repeatedly extracted with 80% ethanol. The combined extracts were subjected to silica gel column chromatography eluted with petroleum ether, CH₂Cl₂, EtOAc, and MeOH, and resulting in four fractions, respectively. The MeOH extract (813.5 g) was separated by silica gel column chromatography eluted with EtOAc-MeOH (20:1-1:1) and re-crystallized to afford compound **1** (115.3 mg). The EtOAc extract (88 g) was separated into seven fractions (A-E) by CC (ODS, MeOH: H₂O 1:9-1:0). Fr. B (22.5 g) was separated over silica gel column chromatography (petroleum ether:EtOAc:MeOH 3:3:0-3:3:2; then Sephadex LH-20 column chromatography (MeOH) to yield compounds **2** (8.1 mg), **3** (3.4 mg), **4** (4.7 mg), **5** (7.2 mg), **6** (10.5 mg), **7** (7.3 mg), **8** (13.9 mg), **9** (15.2 mg), **10** (17.3 mg), **11** (740.8 mg). Fr. C (9.5 g) was purified onto a silica gel column chromatography eluted with CHCl₃:MeOH (100:1-5:1) and followed Sephadex LH-20 column chromatography (MeOH) to yield **12** (22.8 mg), **13** (6.9 mg).

Structural identification

Compound 1 C₆H₆O₃; White solid; ESI-MS m/z 149 [M + Na]⁺; ¹H NMR (CD₃OD, 500 MHz) δ_H: 7.95 (1H, d, J = 5.5 Hz, H-5), 6.41 (1H, d, J = 5.5 Hz, H-6), 2.36 (3H, s); ¹³C NMR (CD₃OD, 125 MHz) δ_C: 152.2 (C-2), 144.6 (C-3), 175.3 (C-4), 114.4 (C-5), 156.3 (C-6), 14.4 (C-7). The NMR data was consistent with the data reported in litera-

ture^[4]. Hence, compound **1** was identified as maltol.

Compound 2 C₆H₆N₂O; white solid; ESI-MS m/z 145 [M + Na]⁺; ¹H NMR (CD₃OD, 600 MHz) δ_H: 9.03 (1H, br, H-2), 8.70 (1H, br, H-6), 8.27 (1H, m, H-4), 7.54 (1H, dd, J = 8.0, 4.9 Hz, H-5); ¹³C NMR (CD₃OD, 150 MHz) δ_C: 152.8 (C-2), 131.5 (C-3), 137.3 (C-4), 125.1 (C-5), 149.5 (C-6), 169.8 (3-CONH₂). The NMR data was identical with the data reported in literature^[5]. Therefore, compound **2** was identified as nicotinamide.

Compound 3 C₉H₁₂N₂O₆; yellow oil; ESI-MS m/z 267 [M + Na]⁺, 511 [2M + Na]⁺, 487 [2M-H]⁻; ¹H NMR (CD₃OD, 600 MHz) δ_H: 7.88 (1H, d, J = 8.1 Hz, H-6), 5.87 (1H, d, J = 4.6 Hz, H-1'), 5.85 (1H, d, J = 8.1 Hz, H-5), 4.27 (1H, t, J = 5.0 Hz, H-2'), 4.18 (1H, t, J = 5.3 Hz, H-3'), 4.08 (1H, m, H-4'), 3.87 (1H, dd, J = 12.7, 2.9 Hz, H-5(a)), 3.77 (1H, dd, J = 12.7, 4.1 Hz, H-5(b)); ¹³C NMR (CD₃OD, 150 MHz) δ_C: 152.5 (C-2), 166.9 (C-4), 103.1 (C-5), 142.7 (C-6), 90.4 (C-1), 70.5 (C-2'), 74.8 (C-3'), 85.4 (C-4'), 61.8 (C-5'). The NMR data was in agreement with the data reported in literature^[6] and determined compound **3** as uridine.

Compound 4 C₉H₁₂N₂O₅; colorless solid; ESI-MS m/z 251 [M + Na]⁺; ¹H NMR (CD₃OD, 500 MHz) δ_H: 7.97 (1H, d, J = 8.1 Hz, H-6), 6.26 (1H, t, J = 6.6 Hz, H-1'), 5.68 (1H, d, J = 8.1 Hz, H-5), 4.37 (1H, m, H-4'), 3.93 (1H, m, H-3'), 3.77 (1H, d, J = 12.0 Hz, H-5(a)), 3.71 (1H, d, J = 12.0 Hz, H-5(b)), 2.28 (1H, m, H-2(a)), 2.18 (1H, m, H-2(b)); ¹³C NMR (CD₃OD, 125 MHz) δ_C: 152.2 (C-2), 166.3 (C-4), 102.6 (C-5), 142.5 (C-6), 88.9 (C-1'), 41.4 (C-2'), 72.3 (C-3'), 86.6 (C-4'), 62.8 (C-5'). Compound **4** was identified as deoxyuridine by comparison with the spectra data reported in literature^[7].

Compound 5 C₁₀H₁₄N₂O₆; colorless solid; ESI-MS m/z 281 [M + Na]⁺, 257 [M-H]⁻, 515 [2M-H]⁻; ¹H NMR (CD₃OD, 500 MHz) δ_H: 7.85 (1H, s, H-6), 5.90 (1H, d, J = 4.5 Hz, H-1'), 4.16 (1H, m, H-2'), 3.99 (2H, m, H-3, H-4'), 3.84 (1H, dd, J = 12.3, 2.7 Hz, H-5(a)), 3.77 (1H, dd, J =

12.3, 3.0 Hz, H-5 (b), 1.98 (3H, s). ^{13}C NMR (CD₃OD, 125 MHz) δ_{C} : 152.5 (C-2), 166.5 (C-4), 111.5 (C-5), 138.4 (C-6), 90.4 (C-1'), 71.3 (C-2'), 75.5 (C-3'), 86.3 (C-4'), 62.3 (C-5'), 12.4 (5-CH₃). The above data was identical with the data reported in literature^[8]. Consequently, compound **5** was identified as thymidine.

Compound 6 C₁₀H₁₄N₂O₅; white crystal (MeOH); ESI-MS m/z 265 [M + Na]⁺, 507 [2M + Na]⁺, 241 [M-H]⁻, 483 [2M-H]⁻; ^1H NMR (CD₃OD, 500 MHz) δ_{H} : 7.67 (1H, s, H-6), 6.28 (1H, t, J = 6.8 Hz, H-1'), 4.46 (1H, m, H-4'), 4.00 (1H, m, H-3'), 3.83 (1H, dd, J = 12.4, 3.5 Hz, H-5(a)), 3.76 (1H, dd, J = 12.5, 4.8 Hz, H-5(b)), 2.36 (2H, m, H-2'), 1.89 (3H, s, CH₃); ^{13}C NMR (CD₃OD, 125 MHz) δ_{C} : 152.6 (C-2), 167.4 (C-4), 112.3 (C-5), 138.4 (C-6), 87.6 (C-1'), 39.7 (C-2'), 71.5 (C-3'), 86.0 (C-4'), 62.2 (C-5'), 12.5 (5-CH₃). The NMR data was in accordance with the data reported in literature^[9], and identified as deoxythymidine.

Compound 7 C₄H₄N₂O₂; colorless solid; ESI-MS m/z 135 [M + Na]⁺; ^1H NMR (CD₃OD, 500 MHz) δ_{H} : 7.40 (1H, d, J = 7.7 Hz, H-6), 5.42 (1H, d, J = 7.7 Hz, H-5); ^{13}C NMR (CD₃OD, 125 MHz) δ_{C} : 152.0 (C-2), 142.7 (C-4), 100.7 (C-5), 164.8 (C-6). By comparison the NMR data with the data reported in literature^[8], compound **7** was identified as uracil.

Compound 8 C₁₃H₁₈O₆; colorless oil; ESI-MS m/z 293 [M + Na]⁺, 563 [2M + Na]⁺, 539 [2M-H]⁻; ^1H NMR (CD₃OD, 500 MHz) δ_{H} : 7.27 (2H, d, J = 8.4 Hz, H-2, H-6), 7.02 (2H, d, J = 8.4 Hz, H-3, H-5), 5.40 (1H, d, J = 2.0 Hz, H-1'), 4.52 (2H, s, H-7), 3.96 (1H, m, H-2'), 3.82 (1H, m, H-3'), 3.62 (1H, dq, J = 12.4, 6.2 Hz, H-5'), 3.44 (1H, t, J = 9.5 Hz, H-4'), 1.20 (3H, d, J = 6.2 Hz, H-6'). ^{13}C NMR (CD₃OD, 125 MHz) δ_{C} : 157.1 (C-1), 129.5 (C-2, C-6), 117.4 (C-3, C-5), 136.4 (C-4), 64.8 (C-7), 99.8 (C-1'), 72.1 (C-2'), 72.2 (C-3'), 73.8 (C-4'), 70.6 (C-5'), 18.0 (C-6'). Comparing NMR data with the data reported in literature^[9], compound **8** was identified as 1-*O*-(4-hydroxymethylphenyl) α -*L*-rhamnopyranoside.

Compound 9 C₁₃H₁₈O₆; colorless oil; ESI-MS m/z 293 [M + Na]⁺, 563 [2M + Na]⁺, 269 [M-H]⁻, 539 [2M-H]⁻; ^1H NMR (CD₃OD, 500 MHz) δ_{H} : 7.40 (2H, m, H-3, H-5), 7.30 (3H, m, H-2, H-4, H-6), 4.92 (1H, d, J = 11.8 Hz, H-7a), 4.65 (1H, d, J = 11.8 Hz, H-7b), 4.34 (1H, d, J = 7.7 Hz, H-1'), 3.88 (1H, dd, J = 11.9, 2.0 Hz, H-6(a)), 3.67 (1H, dd, J = 11.7, 5.3 Hz, H-6(b)). 3.20-3.31 (4H, m, H-2, H-3, H-4, H-5'); ^{13}C NMR (CD₃OD, 125 MHz) δ_{C} : 138.9 (C-1), 129.0 (C-2, C-6), 129.1 (C-3, C-5), 128.5 (C-4), 103.1 (C-1'), 74.9 (C-2'), 77.9 (C-3'), 71.5 (C-4'), 77.9 (C-5'), 62.6 (C-6'). The above data was consistent with the data reported in literature^[10]. Hence, compound **9** was identified as benzyl- β -*D*-glucopyranoside.

Compound 10 C₁₉H₃₀O₇; colorless oil; ESI-MS m/z 393 [M + Na]⁺, 763 [2M + Na]⁺, 369 [M-H]⁻, 739 [2M-H]⁻; ^1H NMR (CD₃OD, 500 MHz) δ_{H} : 5.87 (1H, s, H-4), 5.76 (1H, dd, J = 14.9, 3.5 Hz, H-8), 5.58 (1H, m, H-7), 4.39 (2H, m, H-9, H-1'), 3.81 (1H, d, J = 11.8 Hz, H-6(a)), 3.64 (1H, m, H-6(b)), 3.29 (2H, m, H-4, H-5'), 3.18 (2H, m, H-2, H-3'), 2.66 (1H, d, J = 8.6 Hz, H-6), 2.42 (1H, d, J = 16.7 Hz, H-2a), 2.03 (1H, d, J = 16.9 Hz, H-2b), 1.93 (3H, s, H-13), 1.28 (3H, d, J = 6.3 Hz, H-10), 1.00 (6H, m, H-11, H-12). ^{13}C NMR (CD₃OD, 125 MHz) δ_{C} : 37.1 (C-1), 48.2 (C-2), 201.9 (C-3), 126.1 (C-4), 165.8 (C-5), 56.7 (C-6), 128.8 (C-7), 138.2 (C-8), 76.9 (C-9), 21.0 (C-10), 27.6 (C-11), 28.0 (C-12), 23.8 (C-13), 102.4 (C-1'), 75.2 (C-2'), 78.0 (C-3'), 71.4 (C-4'), 77.9 (C-5'), 62.6 (C-6'). The above data was in accordance with the data reported in literature^[11]. Consequently, compound **10** was identified as (6*R*, 9*R*)-3-oxo- α -ionol-9-*O*- β -*D*-glucopyranoside.

Compound 11 C₂₉H₄₄O₇; white solid; ESI-MS m/z 527 [M + Na]⁺, 503 [M-H]⁻; ^1H NMR (C₅D₅N, 500 MHz) δ_{H} : 6.27 (1H, d, J = 2.3 Hz, H-7), 4.49 (1H, dd, J = 11.3, 2.6 Hz, H-22), 4.25 (1H, s, H-3), 4.18 (1H, d, J = 10.2 Hz, H-2), 3.60 (1H, m, H-9), 3.01 (2H, m, H-5, H-17), 2.66 (1H, td, J = 12.9, 4.7 Hz, H-15a), 2.45 (1H, dd, J = 20.8, 10.2 Hz, H-16a), 2.26-2.13 (3H, m, H-1a, H-15b, H-

25), 2.06 (3H, ddd, $J = 13.8, 11.3, 8.3$ Hz, H-4a, H-16b, H-23a), 1.94 (4H, m, H-1b, H-11a, H-12, H-23b), 1.75 (2H, ddd, $J = 18.1, 17.2, 9.9$ Hz, H-4b, H-11b), 1.50 (3H, s, H-21), 1.40 (2H, m, H-24, H-241a), 1.31 (3H, m, H-27), 1.16 (3H, s, H-18), 1.09 (3H, s, H-19), 1.05 (1H, m, H-24¹b), 0.71 (3H, t, $J = 7.4$ Hz, H-242); ¹³C NMR (C₅D₅N, 125 MHz) δ_c : 38.4 (C-1), 68.5 (C-2), 68.4 (C-3), 32.2 (C-4), 51.3 (C-5), 203.2 (C-6), 121.6 (C-7), 165.6 (C-8), 34.1 (C-9), 38.4 (C-10), 20.8 (C-11), 31.7 (C-12), 47.7 (C-13), 83.9 (C-14), 31.5 (C-15), 21.2 (C-16), 49.7 (C-17), 17.8 (C-18), 24.2 (C-19), 75.5 (C-20), 21.2 (C-21), 85.7 (C-22), 29.4 (C-23), 39.9 (C-24), 41.2 (C-25), 174.4 (C-26), 15.5 (C-27), 26.4 (C-241), 10.0 (C-242). The NMR data was consistent with the data reported in literature^[12]. Hence, compound **11** was identified as capitasterone.

References

- Editor Board of Chinese Materia Medica of the state Administration of Traditional Chinese Medicine. Chinese Materia Medica. Shanghai: Shanghai Science and Technology Publisher, 1999. 2, 782.
- Zhao BS, Gui HS, ZHU YD, *et al.* Research progress in chemical components, pharmacological effectiveness and toxicity of *Psammosilene tunicoides*. *Chin J Exp Tradit Med Form*, 2011, 17: 288-291.
- Zhao J, Wang W, Gao R. Research progress of chemical composition and pharmacological of *Psammosilene tunicoides*. *J Anhui Agric Sci*, 2009, 37: 11526-11529.
- Zhou J, Chen C, Xie Y, *et al.* Studies on liposoluble constituents from fruit of *Sophora japonica* L. *J Shanghai Jiaotong Univ*, 2006, 11: 015.
- Li WC, Yan YM, Zhong HM. Chemical constituents from the roots of *Calotropis procera*. *Nat Prod Res Dev*, 2012, 24: 1390-1392.
- Song Y, Chen GT, Sun BH, *et al.* Chemical constituents of water-soluble part of *Mentha spicata* L. *J Shenyang Pharm Univ*, 2008, 25: 705-707.
- Xu XL, Song FH, Fan X, *et al.* Studies on the chemical constituents of *Ascidian Amaroucium* sp. *Lishizhen Med Mater Med Res*, 2008, 19: 2632-2633.
- Su GC, Zhang S, Qi SH. Chemical constituents of *Amiipathes dichotoma*. *Chin Tradit Herb Drugs*, 2008, 39: 1606-1609.
- Grond S, Papastavrou I, Zeeck A. Novel α -L-Rhamnopyranosides from a Single Strain of *Streptomyces* by supplement-induced biosynthetic Steps. *Eur J Org Chem*, 2002, 2002: 3237-3242.
- Kong CS, Um YR, Lee JI, *et al.* Constituents isolated from *Glehnia littoralis* suppress proliferations of human cancer cells and MMP expression in HT1080 cells. *Food Chem*, 2010, 120: 385-394.
- Kuang H, Yang B, Xia Y, *et al.* Chemical constituents from the flower of *Datura metel* L. *Arch pharm res*, 2008, 31: 1094-1097.
- Hiroshi H, *et al.* Structure of precyasterone, A Novel C₂₉ insect-moulting substance from *Cyathula capitata*. *Chem Pharm Bull*, 1970, 18: 1078-1080.
- Yang Y (杨颖), Cai W (蔡玫), Huang JM (黄俊明). The effect of two forms of extracts of *Radix Panacis Quinquefolii* on immunomodulatory of mice. *South China J Prevent Med (华南预防医学)*, 2003, 1: 15-17.
- Wang YF (王玉凤), Feng LY (凤良元), Yan SQ (鄢顺琴), *et al.* Effect of *Fructus Broussonetiae* on immunological function in immunosuppressive mice induced by cyclophosphamide. *Chin Arch Tradit Chin Med (中华中医药学刊)*, 2008, 26: 1023-1025.
- Koike M, Sekigawa I, Okada M, *et al.* Relationship between CD4(+) / CD8(+) T cell ratio and T cell activation in multiple myeloma; reference to IL-16. *Leuk Res*, 2002, 26: 705-711.
- Al-Sakkaf L, Pozzilli P, Tarn AC, *et al.* Persistent reduction of CD4/CD8 lymphocyte ratio and cell activation before the onset of type 1 (insulin-dependent) diabetes. *Diabetologia*, 1989, 32: 322-325.
- Li R (李荣), Li J (李俊), Hu CM (胡成穆), *et al.* Immunomodulative effect of hesperidin on immunodepressed mice. *Chin Pharm Bull (中国药理学通报)*, 2007, 23: 169-172.

(上接第 670 页)